




Onverwachte bloedingsneiging HIP studie

Dian Winkelhorst
Arts-onderzoeker

Introductie

- **Foetale en Neonatale Alloimmuun Trombocytopenie**
- Pathogenese:
 - HPA incompatibiliteit
 - Alloimmunisatie
 - Trombocytopenie
 - Veranderde functie trombocyt en endotheel
- Incidentie
- Behandeling
- Screening

Antigen	Genotype	Frequentie ¹	FNAIT	Frequentie ²
HPA-1	1aa	72%	Anti-HPA-1b	4%
	1ab	26%		
	1bb	2%	Anti-HPA-1a	79%
HPA-2	2a	7%	Anti-HPA-2b	<1%
	2b	1%		
	2c	2%	Anti-HPA-2a	-
HPA-3	3a	1%	Anti-HPA-3b	-
	3b	1%		
	3c	2%	Anti-HPA-3a	2%
				9%
				1%
				1%
	15ab	42%		
	15bb	23%	Anti-HPA-15a	-





¹ Curtis, et al. Human platelet antigens -2013. *Vox Sanguinis* 2014;106:93-102

² Davoren A, et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. *Transfusion* 2004;44(8):1220-5

Nationaal referentie
ziekenhuis

Nationaal referentie
laboratorium



HIP STUDY

HPA-screening In Pregnancy



HIP studie

Missende informatie:

- Incidentie
 - HPA-1a alloïmmunisaties
 - Klinisch relevante FNAIT
- Risico analyse
 - Screenings platform
- Kosten
 - Kosten-effectiviteit analyse

Opzet studie

- **Studiepopulatie:** Rhesus D en Rhesus c negatieve zwangeren
- **Duur:** 2 jaar
- **Sample size:**
- **Inclusie**




%	Incidence	NL per year Total n = 200.000	Study period Total n = 96.000*
10%	1:12.500	16	7
31%	1:1.300	156	75
12%	1:400	504	240
2.1%	1:50	4.200	2.016

* based on an enrolment of 80%, for a study period of 2 years


Screening platform

Opzet studie




Serologische HPA-1a typering

Flow cytometrie



ELISA



Opzet studie


Studie parameters

Primair:

- HPA-1a alloimmunisatie
- Klinisch relevante FNAIT (perinatale sterfte, ICH of interne bloeding)

Secundair:


- Laboratorium parameters
- Overige tekenen FNAIT
- Behandeling trombocytopenie
- Neonatale morbiditeit



Opzet studie

Antistof screening



- Postpartum
- Luminex
- MAIPA



Opzet studie

Risico analyse

- Antistoftiter
- Fucosylatie



Conclusie

- **HIP studie**
Start begin 2016
- **Evidence** voor besluit over nationaal **screeningsprogramma**
- **Preventie** ernstige complicaties als gevolg van **FNAIT**



HIP STUDY
HPA-screening In Pregnancy

Dank voor uw aandacht

Onderzoeksteam:

Laboratorium Trombocyten/Leukocytenserologie, Sanquin

Drs. Dian Winkelhorst, arts-onderzoeker Sanquin / LUMC

Drs. Porcelijn, Sanquin

Drs. Kamphuis, gynaecoloog LUMC

Dr. Vidarsson, Sanquin

Prof. Dr. Oepkes, perinatoloog LUMC

Prof. Dr. Van der Schoot, Sanquin

Prof. Dr. De Haas, Sanquin / LUMC

